Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Origin of circulating free DNA in patients with lung cancer.

PloS one - 1 Jan 2020

Abe Tomonori, Nakashima Chiho, Sato Akemi, Harada Yohei, Sueoka Eisaburo, Kimura Shinya, Kawaguchi Atsushi, Sueoka-Aragane Naoko

Abstract excerpt

Liquid biopsy has become widely applied in clinical medicine along with the progress in innovative technologies, such as next generation sequencing, but the origin of circulating tumor DNA (ctDNA) has not yet been precisely established. We reported bimodal peaks of long fragment circulating free DNA (cfDNA) of 5 kb and short fragment cfDNA of 170 bp in patients with advanced lung cancer, and both contained ctDNA....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to Culture Media, Conditioned

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Extracellular Vesicles

Share to Liquid Biopsy

Share to Lung Diseases

Share to Neoplasm Metastasis

Share to Transplantation, Heterologous

Source

Open in PubMed Open full text

Identifiers

PMID: 32634139
DOI: 10.1371/journal.pone.0235611
PMCID: PMC7340299

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Origin of circulating free DNA in patients with lung cancer.PMID 32634139Read ↗

Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectivesSemantic proximity Read ↗

Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient ManagementSemantic proximity Read ↗

Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer.Semantic proximity Read ↗

Circulating extracellular vesicles in lung cancer patients are not enriched in tumor-derived DNA fragments as revealed by whole genome sequencingSemantic proximity Read ↗

[Research Progress of Circulating Tumor DNA in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer.Semantic proximity Read ↗

Circulating tumor DNA in liquid biopsy: Current diagnostic limitationSemantic proximity Read ↗

Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.Semantic proximity Read ↗

Malignant pleural effusions for cancer genotyping: A matter of trans-pleural traffic of cell-free tumor DNA.Semantic proximity Read ↗

Circulating DNA and lung cancer.Semantic proximity Read ↗

Tumor-derived cell-free DNA and circulating tumor cells: partners or rivals in metastasis formation?Semantic proximity Read ↗

Distinct Features of Plasma Ultrashort Single-Stranded Cell-Free DNA as Biomarkers for Lung Cancer DetectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.